Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful
immunotherapeutic tools for combating hematological diseases confronted with pressing …

In the past few years, our improved knowledge of acute myeloid leukemia (AML)
pathogenesis has led to the accelerated discovery of new drugs and the development of …

Owing to the more recent positive results with the anti-CD33 immunotoxin gemtuzumab
ozogamicin, therapy against acute myeloid leukemias (AMLs) targeting CD33 holds many …

The adoptive transfer of CD19-specific chimeric antigen receptor engineered T cells (CAR T
cells) resulted in encouraging clinical trials in indolent B-cell malignancies. However, they …

Hematopoietic stem cell transplantation is a highly specialized and unique medical
procedure. Autologous transplantation allows the administration of high-dose chemotherapy …

Monoclonal antibody-based targeted therapy has greatly improved treatment options for
patients. However, long-term efficacy of such antibodies is limited by resistance …

There is a need to improve outcomes for patients with recurrent and/or refractory
hematological malignancies. Immunotherapy holds the promise to meet this need, because …

During oncogenesis, tumor cells present specific carbohydrate chains that are new targets
for cancer immunotherapy. Whereas these tumor-associated carbohydrates (TACA) can be …

Antibody-based immunotherapy represents a promising strategy to target and eliminate
chemoresistant leukemic cells. Here, we evaluated the CD33/CD3-bispecific T cell engaging …

CD33 is a myeloid differentiation antigen with endocytic properties. It is broadly expressed
on acute myeloid leukemia (AML) blasts and, possibly, some leukemic stem cells and has …